Ethyl loflazepate

Jump to: navigation, search
Ethyl loflazepate
Ethyl loflazepate.png
EtLoflazepate0.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  •  ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life51-103 h
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H14ClFN2O3
Molar mass360.7
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Ethyl loflazepate

Articles

Most recent articles on Ethyl loflazepate

Most cited articles on Ethyl loflazepate

Review articles on Ethyl loflazepate

Articles on Ethyl loflazepate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ethyl loflazepate

Images of Ethyl loflazepate

Photos of Ethyl loflazepate

Podcasts & MP3s on Ethyl loflazepate

Videos on Ethyl loflazepate

Evidence Based Medicine

Cochrane Collaboration on Ethyl loflazepate

Bandolier on Ethyl loflazepate

TRIP on Ethyl loflazepate

Clinical Trials

Ongoing Trials on Ethyl loflazepate at Clinical Trials.gov

Trial results on Ethyl loflazepate

Clinical Trials on Ethyl loflazepate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ethyl loflazepate

NICE Guidance on Ethyl loflazepate

NHS PRODIGY Guidance

FDA on Ethyl loflazepate

CDC on Ethyl loflazepate

Books

Books on Ethyl loflazepate

News

Ethyl loflazepate in the news

Be alerted to news on Ethyl loflazepate

News trends on Ethyl loflazepate

Commentary

Blogs on Ethyl loflazepate

Definitions

Definitions of Ethyl loflazepate

Patient Resources / Community

Patient resources on Ethyl loflazepate

Discussion groups on Ethyl loflazepate

Patient Handouts on Ethyl loflazepate

Directions to Hospitals Treating Ethyl loflazepate

Risk calculators and risk factors for Ethyl loflazepate

Healthcare Provider Resources

Symptoms of Ethyl loflazepate

Causes & Risk Factors for Ethyl loflazepate

Diagnostic studies for Ethyl loflazepate

Treatment of Ethyl loflazepate

Continuing Medical Education (CME)

CME Programs on Ethyl loflazepate

International

Ethyl loflazepate en Espanol

Ethyl loflazepate en Francais

Business

Ethyl loflazepate in the Marketplace

Patents on Ethyl loflazepate

Experimental / Informatics

List of terms related to Ethyl loflazepate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ethyl loflazepate[1] (marketed under the brand names Meilax, Ronlax and Victan)[2][3][4] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.[5] In animal studies it was found to have low toxicity, although in rats evidence of pulmonary phospholipidosis occurred with pulmonary foam cells developing with long-term use of very high doses.[6] Its elimination half-life is 51-103 hours.[7] Its mechanism of action is similar to other benzodiazepines. Ethyl loflazepate also produces an active metabolite which is stronger than the parent compound.[8] Ethyl loflazepate was designed to be a prodrug for descarboxyloflazepate, its active metabolite. It is the active metabolite which is responsible for most of the pharmacological effects rather than ethyl loflazepate.[9] The main metabolites of ethyl loflazepate are descarbethoxyloflazepate, loflazepate and 3-hydroxydescarbethoxyloflazepate.[10] Accumulation of the active metabolites of ethyl loflazepate are not affected by those with renal failure or impairment.[11] The symptoms of an overdose of ethyl loflazepate include sleepiness, agitation and ataxia. Hypotonia may also occur in severe cases. These symptoms occur much more frequently and severely in children.[12] Death from therapeutic maintenance doses of ethyl loflazepate taken for 2 – 3 weeks has been reported in 3 elderly patients. The cause of death was asphyxia due to benzodiazepine toxicity.[13] High doses of the antidepressant fluvoxamine may potentiate the adverse effects of ethyl loflazepate.[14]

Ethyl loflazeplate is commercialized in Mexico, but not prescribed very often, under the trade name Victan. It is officially approved for the following conditions:[15][16]

See also

References

  1. DE Patent 2012190
  2. Ba, BB; Iliadis, A; Durand, A; Berger, Y; Cano, JP (Oct 1988). "New approach in bioavailability study of two formulations of ethyl loflazepate". Arzneimittel-Forschung. 38 (10): 1486–9. ISSN 0004-4172. PMID 2904268.
  3. Ba, BB; Iliadis, A; Cano, JP (1989). "Pharmacokinetic modeling of ethyl loflazepate (Victan) and its main active metabolites". Annals of biomedical engineering. 17 (6): 633–46. doi:10.1007/BF02367467. ISSN 0090-6964. PMID 2574017.
  4. "Benzodiazepine Names". non-benzodiazepines.org.uk. Retrieved 2009-04-05.
  5. Ueki, S; Watanabe, S; Yamamoto, T; Shibata, S; Shibata, K; Ohta, H; Ikeda, K; Kiyota, Y; Sato, Y (Nov 1983). "Behavioral effects of ethyl loflazepate and its metabolites". Nippon yakurigaku zasshi. Folia pharmacologica Japonica. 82 (5): 395–409. doi:10.1254/fpj.82.395. ISSN 0015-5691. PMID 6142848.
  6. Mazue, G; Berthe, J; Newmann, AJ; Brunaud, M (Oct 1981). "A toxicologic evaluation of ethyl fluclozepate (CM 6912)". International journal of clinical pharmacology, therapy, and toxicology. 19 (10): 453–72. ISSN 0174-4879. PMID 6116677.
  7. Cautreels, W; Jeanniot, JP (Nov 1980). "Quantitative analysis of CM 6912 (ethyl loflazepate) and its metabolites in plasma and urine by chemical ionization gas chromatography mass spectrometry. Application to pharmacokinetic studies in man". Biomedical mass spectrometry. 7 (11–12): 565–71. doi:10.1002/bms.1200071124. ISSN 0306-042X. PMID 6112027.
  8. Sakai, Y; Namima, M (Apr 1985). "Inhibitory effect on 3H-diazepam binding and potentiating action on GABA of ethyl loflazepate, a new minor tranquilizer". Japanese journal of pharmacology. 37 (4): 373–9. doi:10.1254/jjp.37.373. ISSN 0021-5198. PMID 2861304.
  9. Chambon, JP; Perio, A; Demarne, H; Hallot, A; Dantzer, R; Roncucci, R; Bizière, K (1985). "Ethyl loflazepate: a prodrug from the benzodiazepine series designed to dissociate anxiolytic and sedative activities". Arzneimittel-Forschung. 35 (10): 1573–7. ISSN 0004-4172. PMID 2866771.
  10. Davi, H; Guyonnet, J; Sales, Y; Cautreels, W (1985). "Metabolism of ethyl loflazepate in the rat, the dog, the baboon and in man". Arzneimittel-Forschung. 35 (7): 1061–5. ISSN 0004-4172. PMID 2864933.
  11. Ba, BB; Iliadis, A; Durand, A; Berger, Y; Necciari, J; Cano, JP (1989). "Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man". Fundamental & clinical pharmacology. 3 (1): 11–7. doi:10.1111/j.1472-8206.1989.tb00025.x. ISSN 0767-3981. PMID 2714728.
  12. Pulce C, Mollon P, Pham E, Frantz P, Descotes J (April 1992). "Acute poisonings with ethyle loflazepate, flunitrazepam, prazepam and triazolam in children". Vet Hum Toxicol. 34 (2): 141–3. ISSN 0145-6296. PMID 1354907.
  13. Kamijo, Y; Hayashi, I; Nishikawa, T; Yoshimura, K; Soma, K (Mar 2005). "Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity". Journal of analytical toxicology. 29 (2): 140–4. doi:10.1093/jat/29.2.140. ISSN 0146-4760. PMID 15902983.
  14. Imanishi, T; Onozawa, K; Hayashi, A; Baba, J (Dec 2001). "Effects of fluvoxamine on both the desired anxiolytic effect and the adverse motor incoordination and amnesia induced by benzodiazepines". Nippon yakurigaku zasshi. Folia pharmacologica Japonica. 118 (6): 403–10. doi:10.1254/fpj.118.403. ISSN 0015-5691. PMID 11778459.
  15. "Victan". saludzac.gob.mx/. Retrieved 2009-12-25.
  16. "VICTAN". Farmacia Guerra. Retrieved 2009-12-25.

Linked-in.jpg